Bensheim, 14.9.2022 – Eurox has rebranded as Avextra. The leading manufacturer of cannabis-based medicines Made in Germany will premiere under its new name at the Expopharm Pharmacists\u2019 Congress in Munich from September 14 to 17, 2022. The name Avextra emphasises the company\u2019s clear focus on the highest quality cannabis extracts and its commitment to the development of evidencebased cannabis medicines.<\/p>\n\n\n\n
Cannabis-based medicines have the potential to improve the quality of life of many patient populations around the world but five years after Germany passed its medical cannabis legislation, the evidence gap for these treatments remains significant. Avextra’s vision<\/strong> is to understand the therapeutic potential of this traditional medicinal plant and put it to use in improving the quality of life of patients.<\/p>\n\n\n\n This year the company has embarked upon its first pre-clinical research partnership with the J. W. Goethe University in Frankfurt to compare the cellular responses triggered by the treatment with different cannabis extracts that have been quantitatively analysed to determine exact cannabinoid and terpene content. This is the first step in Avextra\u2019s mission to develop rigorously tested, and regulatory-approved medicines for specific indications.<\/p>\n\n\n\n Avextra is a vertically integrated manufacturer producing cannabis extracts and dronabinol „Made in Germany“ in a 10,000 m\u00b2 state-of-the-art manufacturing facility designed and constructed for the pharmaceutical production of cannabis-based medicines.<\/p>\n\n\n\nInnovation – Studies – Therapeutic Approaches<\/h4>\n\n\n\n
Quality and safety<\/h4>\n\n\n\n
About Avextra<\/h4>\n\n\n\n